France Cough Hypersensitivity Syndrome Therapeutics Market Report 2022 to 2030

France Cough Hypersensitivity Syndrome Therapeutics Market Analysis

$ 3999

The France Cough Hypersensitivity Syndrome Therapeutics Market was valued at $223 Mn in 2022 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030, to $327 Mn by 2030. The main factors driving this industry include the rising prevalence of Cough Hypersensitivity Syndrome, supportive government initiatives, and the development of advanced therapeutics. The industry is primarily dominated by players such as Roche, Pfizer, Sanofi, Novartis, Johnson & Johnson, and GSK among others.

ID: IN10FRPH316 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Riddhi Solanki

Buy Now

France Cough Hypersensitivity Syndrome Therapeutics Market Analysis Executive Summary

The France Cough Hypersensitivity Syndrome Therapeutics Market is at around $223 Mn in 2022 and is projected to reach $327 Mn in 2030, exhibiting a CAGR of 4.9% during the forecast period.

Cough Hypersensitivity Syndrome (CHS) is defined as an excessive response to stimuli, which increases the sensitivity of the cough reflex. This sensitivity frequently results in coughing caused by irritants such as dust, fragrances, or cold air. Common causes of CHS include respiratory infections, gastroesophageal reflux disease (GERD), and exposure to environmental toxins. Symptoms usually include a chronic cough, followed by throat irritation or pain. The treatment for CHS focuses on addressing the underlying causes and controlling the cough reflex. Antitussives, which block the cough reflex, and drugs for GERD or other respiratory tract infections are among the treatment options available. Pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim actively participate in the development of drugs for CHS and related conditions.

France faces a significant burden of chronic cough which affects around 12% of the population. Several factors contribute to market growth including the increasing prevalence of Cough Hypersensitivity Syndrome and subsequently its risk factors like smoking and pollution, supportive government initiatives, and the development of advanced therapeutics. However, conditions such as limited treatment options and efficacy, lack of awareness, and limited local R&D systems restrict the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Upward trend in the prevalence of Cough Hypersensitivity Syndrome: France is experiencing a substantial prevalence of chronic respiratory illnesses such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The estimated prevalence of chronic cough is around 12% of the population. These conditions typically cause CHS, creating a huge patient pool demanding treatment. Air pollution, smoking, and an aging population all contribute to the rising prevalence of CHS, highlighting the need for treatment options.

Supportive government initiatives: The French government has increased its budget towards research, treatment, and support for respiratory conditions like CHS for patients. Reimbursement for CHS therapies encourages healthcare practitioners to prescribe these drugs, improving access, and thereby fostering market growth.

Development of novel therapeutics: Pharmaceutical companies are developing innovative, targeted treatments for CHS like neurokinin-1 (NK-1) receptor antagonists. The availability of improved and more specific treatment options raises patient adoption and drives market expansion.

Market Restraints

Limited treatment options and efficacy: France has no approved drugs for CHS. Treatments for CHS comprise those licensed for disorders like asthma or allergies, having limited efficacy and adverse drug effects for long-term treatment. This prevents patients from seeking diagnosis and treatment while also limiting market expansion.

Lack of awareness: CHS is underdiagnosed owing to its complexity and overlapping symptoms with other respiratory conditions such as asthma or allergies. Insufficient public awareness results in delays in obtaining diagnosis and treatment. The lack of standardization complicates diagnosis and treatment effectiveness.

Limited local R&D: As compared to other respiratory diseases, the pipeline for CHS medicines is limited, with only a few late-stage clinical trials nearing completion. This lack of support restricts market expansion and treatment advances in the future.

Healthcare Policies and Regulatory Landscape

The Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), or National Agency for the Safety of Medicines and Health Products, is the primary regulatory organization in France in charge of drug and pharmaceutical approval and licensing. The Ministry of Solidarity and Health oversees the ANSM, which is in charge of ensuring the safety, efficacy, and quality of therapeutics. The agency is active in all stages of drug research, from pre-clinical studies to post-marketing surveillance, and works with other European regulatory agencies to keep standards consistent across the European Union.

To obtain licensure for drugs in France, pharmaceutical companies must follow a rigorous regulatory process. If the product meets the necessary criteria, ANSM issues a marketing authorization, allowing the drug to be marketed and sold in France.

Navigating the regulatory environment for new entrants in the healthcare industry requires a thorough adherence to the ANSM's rules and regulations like Good Manufacturing Practice (GMP) standards, to ensure product quality and safety.

Competitive Landscape

Key Players

Pfizer
GlaxoSmithKline
Boehringer Ingelheim
AstraZeneca
Johnson & Johnson
Bayer
Novartis
Sanofi
Roche
Merck

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

France Cough Hypersensitivity Syndrome Therapeutics Market Segmentation

By Drug Class

Antitussive Agents
Corticosteroids
Short Acting Beta-2 Agonists
Anti-cholinergic
Antihistamines
Proton Pump Inhibitors
Others

By Route of Administration

Oral
Inhalation
Others

By End Users

Hospitals
Speciality Clinics
Homecare

By Distribution Channel

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.